Oncoceutics

Oncoceutics, Inc. is a privately held company based in Philadelphia, Pennsylvania. With 16 employees, Oncoceutics focuses on the development of innovative treatments for cancer patients. The company specializes in the discovery and development of novel drugs, particularly in the field of selective G protein-coupled receptor antagonists. Their lead compound, ONC201, is an orally administered drug targeting the DRD2 receptor and has shown promise in treating advanced cancers with a favorable safety profile. Oncoceutics differentiates itself through its unique approach to drug discovery, focusing on a novel class of antagonists with potential for broad therapeutic applications in oncology. Their clinical-stage development strategy aims to bring safe and effective treatments to patients battling cancer. For more information about Oncoceutics and its pipeline of innovative cancer therapies, visit their website at oncoceutics.com.